Results 131 to 140 of about 920 (176)
Reactions Weekly, 2011 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate)
Drug Safety, 1992The recommended regimen of etidronic acid (disodium etidronate) for the treatment of Paget's disease of bone is 5mg/kg/day for a period of less than six months. There have, however, been reports of impaired mineralisation of bone and concern that the risk of fracture is increased with this dosage.
K S, Eyres +4 more
openaire +2 more sources
Synthesis of Novel Fatty Acid Derivatives of Etidronic Acid
Synthesis, 2005Abstract: Synthesis of (1-acyloxyethylidene)-1,1-bisphosphonicacids, where the acyl group is decanoyl ( 1a ), lauroyl ( 1b ), palmitoyl( 1c ), stearoyl ( 1d ) or oleoyl ( 1e ) have been described. Preparationof (1-oleoyloxyethylidene)-1,1-bisphosphonic acid tetramethyl es-ter ( 2 ) and its P , P ¢-dimethyl ester (disodium salt 3 and acid form 4 )in ...
Petri A. Turhanen +1 more
openaire +1 more source
Effect of Etidronic Acid on Arterial Calcification in Dialysis Patients
Clinical Drug Investigation, 2006Bisphosphonate drugs, including etidronic acid, are effective agents for the treatment of osteoporosis and may reduce arterial calcification. The aim of this randomised control trial was to characterise the effect of etidronic acid on arterial calcification in patients undergoing chronic haemodialysis.Patients undergoing chronic haemodialysis were ...
Tsuneo, Ariyoshi +4 more
openaire +2 more sources
Anodizing of Aluminum in Etidronic Acid Solution
ECS Meeting Abstracts, 2016Introduction Anodizing of aluminum under appropriate conditions allows the formation of self-ordered porous alumina (porous type oxide film). Ordered porous alumina with large-scale cell sizes and pores is required for expanding the application field in nanotechnology.
Tatsuya Kikuchi +4 more
openaire +1 more source
Etidronic acid for prevention and treatment of osteoporosis
Inpharma Weekly, 1997There are concerns about loss of bone mineral density in postmenopausal women, especially in those who require concomitant corticosteroid therapy. Bisphosphonates are becoming an increasingly popular therapeutic option for treating postmenopausal osteoporosis.
openaire +1 more source